Cargando…

Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial

Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC). Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Alrubaiy, Laith, Hutchings, Hayley A., Louca, Andrea, Rapport, Frances, Watkins, Alan, Sebastian, Shaji, Williams, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784102/
https://www.ncbi.nlm.nih.gov/pubmed/36556259
http://dx.doi.org/10.3390/jpm12122039
_version_ 1784857730475884544
author Alrubaiy, Laith
Hutchings, Hayley A.
Louca, Andrea
Rapport, Frances
Watkins, Alan
Sebastian, Shaji
Williams, John G.
author_facet Alrubaiy, Laith
Hutchings, Hayley A.
Louca, Andrea
Rapport, Frances
Watkins, Alan
Sebastian, Shaji
Williams, John G.
author_sort Alrubaiy, Laith
collection PubMed
description Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC). Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosporin and to compare the differences in the QoL between the two drug treatments over time. Methods: The CONSTRUCT trial examined the cost and clinical effectiveness of infliximab and ciclosporin treatments for acute severe UC. We collected QoL questionnaire data from patients during the active trial period up to 36 months. Following trial completion, we contacted patients postannually for up to a maximum of 84 months. We collected QoL data using a disease-specific (CUCQ, or CUCQ+ for patients who had colectomy surgery) or generic (EQ5D-3L) questionnaire. We analysed QoL scores to determine if there was any difference over time and between treatments in generic or disease-specific QoL. Results: Following initial treatment with infliximab and ciclosporin, patients experienced a statistically significant improvement in both the generic and disease-specific QoL at three months. Generic scores remained fairly static for the whole follow-up period, reducing only slightly up to 84 months. Disease-specific scores showed a much sharper improvement up to 2 years with a gradual reduction in QoL up to 84 months. Generic and disease-specific QoL remained higher than baseline values. There was no significant difference between treatments in any of the QoL scores. Conclusions: Both infliximab and ciclosporin improve QoL following initial treatment for ASUC. QoL scores remain higher than at admission up to 84 months post-treatment.
format Online
Article
Text
id pubmed-9784102
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97841022022-12-24 Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial Alrubaiy, Laith Hutchings, Hayley A. Louca, Andrea Rapport, Frances Watkins, Alan Sebastian, Shaji Williams, John G. J Pers Med Article Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC). Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosporin and to compare the differences in the QoL between the two drug treatments over time. Methods: The CONSTRUCT trial examined the cost and clinical effectiveness of infliximab and ciclosporin treatments for acute severe UC. We collected QoL questionnaire data from patients during the active trial period up to 36 months. Following trial completion, we contacted patients postannually for up to a maximum of 84 months. We collected QoL data using a disease-specific (CUCQ, or CUCQ+ for patients who had colectomy surgery) or generic (EQ5D-3L) questionnaire. We analysed QoL scores to determine if there was any difference over time and between treatments in generic or disease-specific QoL. Results: Following initial treatment with infliximab and ciclosporin, patients experienced a statistically significant improvement in both the generic and disease-specific QoL at three months. Generic scores remained fairly static for the whole follow-up period, reducing only slightly up to 84 months. Disease-specific scores showed a much sharper improvement up to 2 years with a gradual reduction in QoL up to 84 months. Generic and disease-specific QoL remained higher than baseline values. There was no significant difference between treatments in any of the QoL scores. Conclusions: Both infliximab and ciclosporin improve QoL following initial treatment for ASUC. QoL scores remain higher than at admission up to 84 months post-treatment. MDPI 2022-12-09 /pmc/articles/PMC9784102/ /pubmed/36556259 http://dx.doi.org/10.3390/jpm12122039 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alrubaiy, Laith
Hutchings, Hayley A.
Louca, Andrea
Rapport, Frances
Watkins, Alan
Sebastian, Shaji
Williams, John G.
Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_full Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_fullStr Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_full_unstemmed Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_short Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_sort quality of life in patients with acute severe ulcerative colitis: long-term follow-up results from the construct trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784102/
https://www.ncbi.nlm.nih.gov/pubmed/36556259
http://dx.doi.org/10.3390/jpm12122039
work_keys_str_mv AT alrubaiylaith qualityoflifeinpatientswithacutesevereulcerativecolitislongtermfollowupresultsfromtheconstructtrial
AT hutchingshayleya qualityoflifeinpatientswithacutesevereulcerativecolitislongtermfollowupresultsfromtheconstructtrial
AT loucaandrea qualityoflifeinpatientswithacutesevereulcerativecolitislongtermfollowupresultsfromtheconstructtrial
AT rapportfrances qualityoflifeinpatientswithacutesevereulcerativecolitislongtermfollowupresultsfromtheconstructtrial
AT watkinsalan qualityoflifeinpatientswithacutesevereulcerativecolitislongtermfollowupresultsfromtheconstructtrial
AT sebastianshaji qualityoflifeinpatientswithacutesevereulcerativecolitislongtermfollowupresultsfromtheconstructtrial
AT williamsjohng qualityoflifeinpatientswithacutesevereulcerativecolitislongtermfollowupresultsfromtheconstructtrial